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Abstract
Background The Xarelto for Prevention of Stroke in Pa-
tients with Atrial Fibrillation (XANTUS) registry inves-
tigated the safety and efficacy of the factor Xa inhibitor
rivaroxaban. We studied the Dutch XANTUS cohort to
a ssess drug safety and prescription patterns in the Nether-
lands.
Methods The XANTUS registry was designed as a Euro-
pean prospective, observational study among patients with
non-valvular atrial fibrillation. Major bleeding and all-cause
mortality were assessed every three months during a 1-year
follow-up period. In this Dutch sub-cohort we were also
specifically interested in dosing regimens and the incidence
and reasons for temporary or permanent discontinuation.
Results Patients (n = 899) had a mean age of 69 (SD ± 9)
years and 64.8% were male. The median CHA2DS2-VASc
score was 2 (IQR 2–4) and the median HAS-BLED score
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was 2 (IQR 1–2). Major bleeding occurred in 19 patients
(2.4 per 100 patient-years) and 8 patients (1.0 per 100 pa-
tient-years) died during the 1-year follow-up period. Ac-
cording to renal function, label-discordant dosing was ob-
served in 48 (8.3%) patients. Finally, 124 patients (13.8%)
reported a temporary interruption of rivaroxaban treatment
and 11.8% switched to another oral anticoagulant therapy
after permanent discontinuation of rivaroxaban.
Conclusion In the Dutch subset of the XANTUS registry,
we observed low rates of major bleeding and label-discor-
dant dosing and high persistence rates during one year of
follow-up in patients receiving rivaroxaban in routine clini-
cal practice. However, documenting the motivation of novel
oral anticoagulant (NOAC) type and dose is essential to
study label-discordant prescription, a potential safety para-
dox and identify patient characteristics to optimise NOAC
use and adherence.
Keywords Atrial fibrillation · Rivaroxaban · XANTUS ·
Non-VKA oral anticoagulation
Introduction
The landscape concerning antithrombotic treatment of pa-
tients with non-valvular atrial fibrillation (AF) has changed
in the last decade. First, anticoagulant treatment showed its
superiority as compared with antiplatelet agents for stroke
prevention [1–3]. Second, new oral anticoagulant agents
have been approved as an alternative for vitamin K antag-
onists (VKAs) [4–7]. As a class, these agents, commonly
referred to as non-VKA oral anticoagulants (NOACs), re-
duce the risk of intracranial haemorrhage by approximately
50% and of major bleeding by approximately 15% in com-
parison with VKA treatment [8]. Consequently, the recently
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updated European guidelines on the management of AF rec-
ommend the use of NOAC treatment over VKA treatment
in eligible patients [9].
In the context of a long history of well-monitored VKA
treatment, real-world data on compliance and management
of complications were topics of interest at the time of the
implementation of the NOACs. Therefore, at the request of
the Dutch Ministry of Health, Welfare and Sports, a guid-
ance document was published in November 2012 to facili-
tate a gradual implementation of the NOACs in daily clini-
cal practice [10]. In accordance with other NOAC registries
[11–15], in the Xarelto for Prevention of Stroke in Patients
with Atrial Fibrillation (XANTUS) registry the investiga-
tors collected data on the safety of rivaroxaban in a ‘real-
world’ setting. In addition, ischaemic complications, drug
dosing and discontinuation rates were assessed [16]. In the
present study, we evaluated the abovementioned outcome
measures for the Dutch population of the XANTUS reg-
istry.
Methods
XANTUS is a European prospective, post-authorisation,
observational phase IV study in patients with non-valvu-
lar AF treated with rivaroxaban for stroke prevention. Its
design has been published previously [17].
Study population and follow-up
In brief, patients were eligible if they were diagnosed with
non-valvular AF, started rivaroxaban therapy and provided
written informed consent. All patients were screened se-
quentially and data were documented in an anonymous log
file. Enrolment in the XANTUS registry took place be-
tween June 2012 and December 2013. For the purpose of
this study we selected patients enrolled in the Netherlands.
Decisions with regard to rivaroxaban prescription (e. g. dose
selection, interruption and discontinuation) were at the dis-
cretion of the treating physician.
Study outcomes
The primary study outcomes were related to the safety of
rivaroxaban and comprised major bleeding events and all-
cause mortality [16]. Major bleeding was defined accord-
ing to the criteria suggested by the International Society of
Thrombosis and Haemostasis (ISTH) [18]. A bleeding event
was considered fatal when death occurred within 30 days
of the bleeding event.
Secondary outcomes included clinically overt throm-
boembolic events (stroke, non-central nervous systemic
embolism, transient ischaemic attack, myocardial infarc-
tion) and any non-major bleeding.
With regard to guideline adherence, we evaluated the
dosing regimen in the perspective of renal function. Fur-
thermore, we evaluated temporary and permanent discon-
tinuation rates, including the reported reasons.
Statistical considerations
Given the exploratory purpose of the study, statistical analy-
ses were descriptive. Data were depicted as means and stan-
dard deviations (SD) or medians and interquartile ranges
(IQR), whichever was appropriate. Categorical variables
were depicted as frequencies and percentages.
Results
Baseline characteristics
Among the 6784 participants of the XANTUS registry, a
total of 899 (13.3%) were enrolled in the Netherlands. The
mean age of the Dutch patients was 69.2 (SD ± 8.9) years
and 583 (64.8%) were male (Table 1). With regard to risk
scores, the median CHA2DS2-VASc score was 2 (IQR 2–4)
and the median HAS-BLED score was 2 (IQR 1–2). Data
concerning renal function were available in 580 (64.5%)
patients. A total of 53 (5.9%) patients had a creatinine clear-
ance of <50 ml/min.
Before enrolment in the registry, 779 patients (86.7%)
were using antithrombotic therapy, which included VKA in
576 (64.1%) patients. Acetylsalicylic acid as monotherapy
was reported in 120 (13.3%) patients prior to treatment with
rivaroxaban (Table 1).
With regard to follow-up, 764 (85.0%) fulfilled the
1-year observation period.
Study outcomes
A total of 21 major bleeding events were observed in 19
(2.1%) patients (Table 2). Bleeding events occurred most
frequently in the gastrointestinal tract, followed by intracra-
nial bleeding (Table 3). Gastrointestinal bleeding was re-
ported 9 times in 7 patients. Fifteen patients reported un-
scheduled contact with a physician, in 10 patients medical
intervention was necessary. With regard to all-cause mor-
tality, a total of 8 (0.9%) patients died during follow-up.
Three deaths were considered to be caused by fatal bleed-
ing and 2 were cardiovascular in origin. In addition, cancer,
infectious disease and an unclassified cause were reported
once.
Concerning the secondary outcomes, 15 thromboembolic
events were reported in 13 (1.4%) patients. These com-
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Table 1 Baseline character-
istics of Dutch patients in the
XANTUS study (n = 899)
Age (years), mean ± SD 69.2 ± 8.9
≥75, n (%) 254 (28.3%)
Gender (male), n (%) 583 (64.8%)
Weight (kg), mean ± SD 85.8 ± 17.1
Creatinine clearance (ml/min), n (%)
15–29 5 (0.6%)
30–49 48 (5.3%)
≥50 527 (58.6%)
Missing 319 (35.5%)
Atrial fibrillation type, n (%)
First diagnosed 170 (18.9%)
Paroxysmal 473 (52.6%)
Persistent 98 (10.9%)
Permanent 158 (17.6%)
CHADS2 score, median (IQR) 1 (1–2)
<2 556 (61.8%)
≥2 343 (38.2%)
CHA2DS2-VASc score, median (IQR) 2 (2–4)
HAS-BLED score, median (IQR) 2 (1–2)
≥3 161 (17.9%)
Prior stroke/TIA/non-CNS SE, n (%) 107 (11.9%)
Congestive heart failure, n (%) 58 (6.5%)
Hypertension, n (%) 550 (61.2%)
Coronary artery disease, n (%) 93 (10.3%)
Peripheral artery disease, n (%) 47 (5.2%)
Diabetes mellitus, n (%) 143 (15.9%)
Prior use of antithrombotic therapy, n (%) 779 (86.7%)
VKA 559 (62.2%)
Direct thrombin inhibitor 14 (1.6%)
ASA 120 (13.3%)
SD standard deviation, BMI body mass index, IQR interquartile range, TIA transient ischaemic attack,
CNS central nervous system, SE systemic embolism, VKA vitamin K antagonist, ASA acetylsalicylic acid
Creatinine clearance calculated using the Cockcroft-Gault formula
Table 2 Study endpoints Incidence proportion,
n (%)
Incidence rate, events
per 100 patient-years
(95% CI)
Primary outcomes Major bleeding 19 (2.1%) 2.4 (1.4–3.7)
All-cause mortality 8 (0.9%) 1.0 (0.4–2.0)
Secondary outcomes Thromboembolic event 13 (1.4%) 1.6 (0.9–2.8)
Non-major bleeding 142 (15.8%) 19.6 (16.5–23.1)
CI confidence interval
prised 4 ischaemic strokes, 4 myocardial infarctions and
7 transient ischaemic attacks.
Any non-major bleeding occurred 195 times in 142
(15.8%) patients (Table 3). A total of 68 patients reported
unscheduled contact with a physician; subsequent medical
intervention was taken in 26 patients. With regard to the
impact of bleeding, patient discomfort (i. e. pain or impair-
ment of daily life activities) was reported in 14 (73.7%)
cases with major bleeding events and in 38 (26.8%) in
patients with non-major bleeding complications.
Rivaroxaban prescription and dosing regimens
Rivaroxaban was prescribed in a dose of 20 milligrams (mg)
once daily in 817 (90.8%) of the patients. These patients had
a median HAS-BLED score of 2 (1–2) and 133 (16.3%) had
a HAS-BLED score ≥3. Among the patients with a daily
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Table 3 Bleeding complications according to location
Number of patients (%)
Major bleeding 19 (2.1%)
Gastrointestinal 7 (0.8%)
Intracranial 4 (0.4%)
Genitourinary 2 (0.2%)
Conjunctival 1 (0.1%)
Intraocular 1 (0.1%)
Musculoskeletal 1 (0.1%)
Skin 1 (0.1%)
Surgery site 1 (0.1%)
Not reported 1 (0.1%)
Non-major
bleeding
142 (15.8%)
Nasal 56 (6.2%)
Genitourinary 27 (3.0%)
Skin 26 (2.9%)
Gastrointestinal 21 (2.3%)
Other 12 (1.3%)
Fig. 1 Renal function according to initially prescribed dose CrCl cre-
atinine clearance
dose of 15 mg, the median HAS-BLED score was 2 (2–3)
and 26 (41.8%) had a HAS-BLED score ≥3. The remaining
3 patients received an initial daily dose of 10 mg.
According to renal function, label-discordant dosing was
observed in 48 (8.3%) patients; 2 patients received a daily
dose of 10 mg, 26 patients received 15 mg discordantly and
20 patients received 20 mg not according to label (Fig. 1).
Major bleeding occurred in 17 (2.1%) and 2 (2.5%) patients
treated with rivaroxaban 20 mg and 15 mg, respectively.
Discontinuation rates
During follow-up, 124 patients (13.8%) reported a tem-
porary interruption of rivaroxaban treatment. Reasons in-
cluded surgery (n = 60), bleeding (n = 35) and non-bleeding
adverse events (n = 29). The median duration of interruption
was 3 days (IQR 2–8).
Study treatment was discontinued in 147 (16.4%) pa-
tients, half of whom discontinued within 3 months after
initiation (Fig. 2). The main documented reasons for per-
manent discontinuation were patient decision (n = 33, 23%)
or an adverse event (n = 27, 19%) (Fig. 2a). The majority
of patients (n = 84) who stopped study treatment switched
to VKAs, followed by a switch to a different NOAC (n =
22).
Discussion
Main outcomes and patient population
In this substudy of the XANTUS registry we assessed
the safety of rivaroxaban in a ‘real-world’ situation in
the Netherlands. The Dutch subgroup consisted of less
permanent AF patients compared with the overall XAN-
TUS cohort [16]. Subsequently, this largely explains the
observed differences in patient characteristics between the
two cohorts, i. e. a younger and healthier Dutch subgroup.
The inclusion of more paroxysmal AF patients in the
Netherlands likely relates to national policy which advo-
cates the initial use of NOACs in first detected AF opposed
as to actively switching patients from VKAs to NOACs.
Among the 899 patients major bleeding rates, which have
been published previously, were low and comparable with
the overall XANTUS cohort. Similar observations were
made for the rates of thromboembolic events and all-cause
mortality [16]. Furthermore, we observed that over 90%
of patients were treated according to label in daily clinical
practice, and that 1-year persistence rate was over 80%.
Major bleeding events were observed less frequently
than in the overall XANTUS cohort (2.1/100 patient-years)
and the ROCKET-AF study (3.5/100 patient-years). In both
the overall XANTUS cohort and the Dutch subset over 40%
of the major bleeding complications had a gastrointesti-
nal origin. Among the patients randomised to rivaroxaban
treatment in the ROCKET-AF trial, gastrointestinal bleed-
ing comprised over 50% (224/395) of the major bleeding
complications. The event rate for intracranial haemorrhage,
often considered to be the most devastating bleeding com-
plication, accounted for 20% of the major bleeding compli-
cations in both the overall and the Dutch XANTUS cohort,
as compared with 15% in the ROCKET-AF trial population.
With regard to ischaemic complications and mortality,
event rates in the Dutch XANTUS cohort were low com-
pared with the ROCKET-AF population. The differences
in event rates for ischaemic stroke (0.5 vs 1.4/100 pa-
tient-years) and all-cause mortality (1.0 vs 1.9/100 patient-
years) might be explained by important differences in base-
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Fig. 2 Permanent (a) and
temporary (b) reason of discon-
tinuation among patients who
stopped study treatment
line characteristics. Of the Dutch XANTUS patients, 28%
were aged 75 years or over, which is less than in the
overall XANTUS cohort (38%) or ROCKET-AF popula-
tion (43%). Among the ROCKET-AF population, all pa-
tients had a CHADS2 score of at least 2 points. In contrast,
only 38% of the Dutch XANTUS patients had a CHADS2
score ≥2. As for renal function, 6% had a creatinine clear-
ance below 50 ml/min, whereas these percentages were 9%
and 20% for the overall XANTUS and ROCKET-AF co-
horts, respectively. Note that the ROCKET-AF trial in-
tended to include a high-risk population. As such, the in-
clusion criteria were different from the XANTUS registry.
Initial prescription of NOACs in a low-risk population is
in line with the recommendations of the Dutch Ministry of
Health, Welfare and Sport, proposing a careful introduction
of NOACs in the Netherlands. Noteworthy, most treatment
switches from rivaroxaban were to VKAs (84/143), indicat-
ing the relative novelty of NOACs during the study period.
In addition, the gradual uptake of NOAC treatment in the
Netherlands has been described recently [19].
Dosing issues
In 8% of the Dutch XANTUS participants, rivaroxaban was
prescribed in an inappropriate dose. As stated in the sum-
mary of product characteristics (SmPC), dose recommen-
dations are particularly based upon renal function. How-
ever, prescribing physicians were probably influenced by
other factors. First, previous guidelines recommended the
lower NOAC dose for patients with a HAS-BLED score ≥3
[20]. Current guidelines do not recommend dose reductions
based on bleeding risk scores [9].
It is important to state that the rationale behind the dose-
reduction strategies in the randomised trials was to avoid
overdosing in specific patient groups. In a recently pub-
lished sub-analysis of the ARISTOTLE trial, the authors
state that inappropriate dosing could lead to preventable is-
chaemic strokes and that patients therefore should be treated
with the studied dose [21]. A similar statement is found
in the European Society of Cardiology guidelines on AF
management [9]. Consequently, other perceived bleeding
risk factors, including a prior bleeding event or concomi-
tant use of antiplatelet agents, should not per se lead to
prescription of a reduced dose. With regard to prior bleed-
ing, exploratory data from the RE-LY trial did not support
a dose-lowering strategy after a bleeding episode [22].
Nevertheless data on creatinine clearance were missing
in over one-third of the patients. Whether this is because of
clinical judgment (no need to measure the creatinine clear-
ance) or due to the observational nature of the study (not
reported) remains speculative. The observed low rates of
stroke and bleeding and limited use of low-dose rivarox-
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aban support the former. Dose reduction during follow-up
was uncommon, perhaps this is due to limited follow-up of
creatinine clearance measurements or to the relatively low
risk profile of the population.
All in all, these data advocate to prescribe NOACs in
doses as evaluated in trial settings and be aware of the safety
paradox: a lower (N)OAC dose does not equal a low(er) risk
of bleeding and preserved efficacy [22, 23].
Discontinuation
Despite good treatment satisfaction, 1 out of 6 patients per-
manently discontinued treatment with rivaroxaban during
the follow-up period, with a peak during the first quarter.
Although the motivation for discontinuation of rivaroxaban
was missing in a substantial number of patients, patient
decisions and adverse events were reported. Nonetheless,
a persistence rate over 80% was reported in the Dresden
registry as well, in which bleeding complications and non-
bleeding side effects accounted for the majority of treatment
discontinuations [24].
The majority of patients (106/147) switched to either
VKA treatment (n = 84) or another NOAC (n = 22) after
rivaroxaban discontinuation. The relatively high number of
patients switching to VKA treatment should be placed in
a time perspective. The remaining patients might have had
a temporary indication for anticoagulation therapy. Given
the considerable proportion of paroxysmal AF and young
(e. g. <65 years of age) patients together with a CHA2DS2-
VASc score of 0 or 1, this temporary indication could be re-
lated to a rhythm control strategy (e. g. peri-ablation or car-
dioversion). Despite the relatively high percentage (13%) of
patients treated with antiplatelet therapy for stroke preven-
tion before study entry, observations from this study were
reassuring, as a switch from rivaroxaban to antiplatelet ther-
apy was uncommon (<1%). Treatment was interrupted tem-
porarily in 13.8% of the patients in the study cohort, a pro-
portion slightly higher compared with the overall XANTUS
cohort (8.8%). As compared with the ROCKET-AF popu-
lation (2165/7131 patients treated with rivaroxaban) inter-
ruption rates were similar, as were the main reasons for
interruption, which included surgery and bleeding events
[25].
Limitations
Although the first real-world data concerning NOAC use
in the Netherlands are very valuable, they should be in-
terpreted in the context of guideline recommendations at
the time the study was conducted (2012–2013). At present,
NOACs are prescribed more liberally, and the current ESC
guideline has endorsed NOACs as the preferred treatment
[9]. Second, we should acknowledge that data on renal func-
tion were not available at the time of prescribing rivarox-
aban in one-third of the patients. Again, this observation
deserves particular clinical attention as dose reduction in
the ROCKET-AF randomised controlled trial (RCT) and
dose recommendations in the SmPC rely particularly on
renal function. Finally, the study cohort was a relatively
healthy population. Initial selection of patients even more
healthy than in the respective RCT is common with the
introduction of new drugs. Although this exemplifies real-
life, we must be aware of underrepresentation of subgroups
of patients in an RCT and ‘real-life’ setting. For instance,
whether the observations can be extrapolated to a very high-
risk population is questionable. This question will probably
be answered by the randomised FRAIL-AF trial, which will
be conducted in the Netherlands [26].
Conclusion
In the Dutch subset of the XANTUS registry, we observed
low rates of major bleeding and label-discordant dosing
and high persistence rates during one year of follow-up in
patients receiving rivaroxaban in routine clinical practice.
However, documenting the motivation of NOAC type and
dose is essential to study label-discordant prescription, a po-
tential safety paradox and identify patient characteristics to
optimise NOAC use and adherence.
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